Diplomat Pharmacy Inc (DPLO) was Downgraded by Credit Suisse to ” Underperform”. Earlier the firm had a rating of “Neutral ” on the company shares. Credit Suisse advised their investors in a research report released on Nov 23, 2016.
Many Wall Street Analysts have commented on Diplomat Pharmacy Inc. Shares were Reiterated by Mizuho on Nov 3, 2016 to “Neutral” and Lowered the Price Target to $ 17 from a previous price target of $39 .Diplomat Pharmacy Inc was Downgraded by Avondale to ” Mkt Perform” on Nov 3, 2016. Diplomat Pharmacy Inc was Downgraded by Leerink Partners to ” Mkt Perform” on Nov 3, 2016.
On the company’s financial health, Diplomat Pharmacy Inc reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Nov 2, 2016. Analyst had a consensus of $0.24. The company had revenue of $1181.00 million for the quarter, compared to analysts expectations of $1258.11 million. The company’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.
Diplomat Pharmacy Inc closed down -0.42 points or -2.78% at $14.68 with 6,42,200 shares getting traded on Monday. Post opening the session at $15.1, the shares hit an intraday low of $14.54 and an intraday high of $15.19 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Sep 16, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 20,000 shares at $30.12 per share price. According to the SEC, on Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at $33.60 per share price. On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at $35.08 per share price, according to the Form-4 filing with the securities and exchange commission.
Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.